Stay updated with breaking news from Sciences Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The biomedical giant best known for its Cologuard at-home colon cancer screening test reported third-quarter net income of $0.8 million, or $0.00 per share, on revenue of $628 million.
Unveiling the Strengths and Challenges: A Deep Dive into Exact Sciences Corp (EXAS) SWOT Analysis
/PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will...
On Tuesday, Cathie Wood-led Ark Invest made significant trades, with a notable purchase of shares in Robinhood Markets Inc (NASDAQ:HOOD) while offloading positions in Coinbase Global Inc (NASDAQ:COIN) a
The Wisconsin Biohealth Tech Hub now can apply for up to $70 million in federal funds to accelerate developments in biotech and personalized medicine.